Imeglimin is a novel oral anti-diabetic drug developed by Merck KGaA and approved by the European Medicines Agency in November 2019. It is the first in a new class of diabetes medications called 'glimins' that works by activating a protein in the body called AMPK. Imeglimin is indicated for use in adults with type 2 diabetes to improve glycaemic control in combination with other glucose-lowering therapies, such as diet and exercise, and may also help to reduce body weight. It is taken as a once-daily tablet, with or without food.
Imeglimin is an investigational drug, meaning it's currently undergoing clinical trials to see if it's safe and effective for treating a specific condition. The target condition for Imeglimin is type 2 diabetes.
Here's what we know about Imeglimin so far:
- Mechanism: It belongs to a new class of oral diabetes medications called glimins. Imeglimin works in several ways to improve blood sugar control in type 2 diabetes. It appears to:
- Increase insulin secretion from the pancreas in response to blood sugar levels.
- Improve insulin sensitivity, allowing cells to better utilize insulin for glucose uptake.
- Reduce gluconeogenesis, which is the production of glucose by the liver.
- Potentially offer some protection for pancreatic beta cells, which are responsible for insulin production.
- Benefits: Due to its multifaceted approach, Imeglimin has shown promise in clinical trials for improving glycemic control in patients with type 2 diabetes. It may also be beneficial as monotherapy (single drug treatment) or in combination with other diabetes medications.
- Approval Status: Imeglimin is not currently approved by the US Food and Drug Administration (FDA) or other major regulatory bodies. More clinical trials are needed to confirm its efficacy and safety profile before it becomes available for prescription.
Important Points to Remember:
- Imeglimin is still under development and not a commercially available treatment for type 2 diabetes.
- If you have type 2 diabetes, consult your doctor regarding the best course of treatment for you based on your individual needs.